Fennec Pharmaceuticals (NASDAQ: FENC) is one of 633 publicly-traded companies in the “DRUGS” industry, but how does it compare to its competitors? We will compare Fennec Pharmaceuticals to related businesses based on the strength of its dividends, earnings, risk, analyst recommendations, valuation, institutional ownership and profitability.
This is a breakdown of recent ratings and price targets for Fennec Pharmaceuticals and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Fennec Pharmaceuticals Competitors||3189||10127||25932||727||2.61|
Earnings and Valuation
This table compares Fennec Pharmaceuticals and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Fennec Pharmaceuticals||N/A||-$2.78 million||-23.93|
|Fennec Pharmaceuticals Competitors||$1.80 billion||$141.03 million||-7.25|
Fennec Pharmaceuticals’ competitors have higher revenue and earnings than Fennec Pharmaceuticals. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
44.9% of Fennec Pharmaceuticals shares are held by institutional investors. Comparatively, 47.2% of shares of all “DRUGS” companies are held by institutional investors. 10.7% of Fennec Pharmaceuticals shares are held by company insiders. Comparatively, 16.0% of shares of all “DRUGS” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This table compares Fennec Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Fennec Pharmaceuticals Competitors||-3,672.93%||-135.05%||-29.45%|
Risk & Volatility
Fennec Pharmaceuticals has a beta of 0.09, meaning that its share price is 91% less volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals’ competitors have a beta of 0.30, meaning that their average share price is 70% less volatile than the S&P 500.
Fennec Pharmaceuticals competitors beat Fennec Pharmaceuticals on 8 of the 13 factors compared.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company’s lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children’s Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.